Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00073697
Status:
COMPLETED
Last Update Posted:
2012-01-11
First Post:
2003-12-02
Brief Title:
Treatment of Depression in Adults
Sponsor:
University of Pittsburgh
Organization:
University of Pittsburgh
Study Overview
Official Title:
Depression The Search for Treatment-Relevant Phenotypes
Status:
COMPLETED
Status Verified Date:
2012-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will determine how certain features of depressed individuals affect their responses to depression treatment
Detailed Description:
Major depression is a serious condition that can have devastating functional consequences Although numerous depression studies have been conducted understanding of how best to achieve long-term recovery remains limited This study will assess the mood personality pharamcokinetic and genetic characteristics of depressed participants to determine the effects of these features on treatment response
This study will be conducted at two international treatment sites including the University of Pittsburgh and the University of Pisa Italy Participants will be randomly assigned to receive either interpersonal psychotherapy IPT or escitalopram pharmacotherapy for a minimum of 32 weeks or approximately 8 months Participants whose symptoms become stabilized will continue the initial treatment for another 6 months those who do not will have the second treatment added to their regimen until remission occurs Clinical evaluations and questionnaires will be used to assess participants
This study will be conducted at two international treatment sites including the University of Pittsburgh and the University of Pisa Italy Participants will be randomly assigned to receive either interpersonal psychotherapy IPT or escitalopram pharmacotherapy for a minimum of 32 weeks or approximately 8 months Participants whose symptoms become stabilized will continue the initial treatment for another 6 months those who do not will have the second treatment added to their regimen until remission occurs Clinical evaluations and questionnaires will be used to assess participants
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01MH065376 | NIH | None | None |
| DSIR 83-ATAS | US NIH GrantContract | None | httpsreporternihgovquickSearchR01MH065376 |